Rigel Pharmaceuticals published final Phase 1/2 ARROW data for pralsetinib (GAVRETO) in metastatic RET fusion-positive non-small cell lung cancer in the Journal of Clinical Oncology, extending follow-up by an additional 42 months. The company reported robust and durable responses with a manageable safety profile. Across 259 patients with measurable disease, overall response rate reached 70%, including 7% complete responses and 63% partial responses. The company also highlighted activity in patients with measurable CNS metastases at baseline. On safety, the publication notes three treatment-related deaths occurred in Asia in treatment-naive patients, attributed to pneumonia (n=2) and interstitial lung disease and rhabdomyolysis (n=1 each). Rigel said no new safety signals were observed and no hypersensitivity reactions occurred in patients after prior immunotherapies.